TY - JOUR ID - TI - Results of Minimal Dosage Propranolol in the Management of Infantile Haemangioma AU - Zakaria A. Aarajy*, Nuas Hasab Jaafar*, Ahmed Khalaf Jasim**, Ahmed Ibraheim Ismaeel* PY - 2019 VL - 18 IS - 1 SP - 10 EP - 17 JO - Iraqi Postgraduate Medical Journal المجلة العراقية للاختصاصات الطبية SN - 83601608 98932708 AB - ABSTRACT:BACKGROUND:Infantile haemangioma one of the most common tumour of new borns , a safe and effective treatmentoptions are under ongoing research .OBJECTIVE:The authors show the effectiveness and safety of low dose propranolol as a method for infantilehaemangioma treatment .METHOD:In this study twenty- four patients with infantile haemangioma in different anatomical locations weretreated with oral propranolol and the result were assessed in a retrospective analysis of the resultspatients were kept on 0.25 mg/kg/day for one month , then on 0.5mg/kg/day in 2 divided doses foranother one month , in the third month the dose will be increased to 1 mg/kg/day in 2 divided doses ,then the propranolol were given in a maintenance dose ranging between 1-1.5 mg/kg/day in 2 divideddoses according to the clinical response .The duration of treatment ranging from 6-18 months as asmall dose increasing over a long time .RESULTS:We had achieved excellent result in most of our patients, with reduction of size and fade of color ofhemangioma within 1 month from the initiation of treatment, when we stop the treatment no relapseswere noticed during our follow up period after finishing the course.CONCLUSION:Propranolol is one of the safest and most effective treatment options for the infantile haemangiomaeven in low dose, with lower relapse rates and minimal consecutive side effects and drawbacks.

ER -